o-(4-ethoxybutyl)berbamine has been researched along with Hepatocellular Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z; Liu, J; Qi, S; Wang, T; Zhang, J; Zhu, H | 1 |
| Fang, BJ; Liao, LM; Liu, JW; Yang, SG; Yu, ML; Zhao, RC | 1 |
2 other study(ies) available for o-(4-ethoxybutyl)berbamine and Hepatocellular Carcinoma
| Article | Year |
|---|---|
The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.
Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Benzylisoquinolines; Calmodulin; Carcinoma, Hepatocellular; Cell Division; Cell Survival; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Drug Synergism; Fluorouracil; Inhibitory Concentration 50; Liver Neoplasms, Experimental; Mice; Neoplasm Transplantation; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice.
Topics: Animals; Antineoplastic Agents; Benzylisoquinolines; Calmodulin; Carcinoma, Hepatocellular; Doxorubicin; Drug Synergism; Liver Neoplasms; Mice; Mice, Inbred BALB C | 2004 |